IVL

Across TCGA pan-cancer cohorts, IVL Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IVL data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IVL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IVL expression acts as an unfavorable survival marker.

LUAD, PCPG, and UCEC are the cancer types where IVL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.345	0.686	.007	21	view →
PCPG	DFS	Median	All	0.070	0.936	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.245	0.760	.004	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IVL–LUAD (DFS)

Open the LUAD breakdown →